H.C. Wainwright launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and $6 price target. The stock closed at $2.04 on Dec. 9. Affimed is a clinical-stage biotechnology company focused on developing innate...
Cantor Fitzgerald initiated coverage of Affimed N.V. (NASDAQ:AFMD) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.23 on Feb. 22. Affimed, which is one of Cantor’s top picks for...
Stifel launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and price target of $12. The stock closed at $5.85 on Sept. 29. Affimed is a clinical-stage biotechnology company focused on bispecific antibody...